Cite
HARVARD Citation
Kristeleit, R. et al. (2022). Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet oncology. 23 (4), pp. 465-478. [Online].